GENETIC TECHNOLOGIES LIMITED — Board/Management Information 2013

Dec 11, 2013

==> picture [592 x 69] intentionally omitted <==

==> picture [592 x 69] intentionally omitted <==

ASX ANNOUNCEMENT 12 December 2013

Appointment of Independent Non-Executive Director

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to advise that Dr. Paul Kasian has today been appointed a Non-Executive Director of the Company. An ASX Appendix 3X on behalf of Dr. Kasian is attached.

Dr. Kasian is an experienced executive director with demonstrated domestic and international success in funds management, encompassing senior leadership, investment and risk roles. Previously, Dr. Kasian has held senior leadership positions in a number of investment groups, including Chief Investment Officer at HSBC Asset Management; Head of HSBC Global Financial Team; Founding Director Accordius and Founding Director Wallara Asset Management.

Dr. Kasian has significant funds management experience in Australia leading investment in the healthcare and life sciences sector. He was previously a Project Leader at ICI Australia providing advice on biotech projects and acquisitions. He holds a PhD in Microbiology and a Master of Business Administration, both from the University of Melbourne.

Genetic Technologies’ Chairman, Dr. Mal Brandon commented on the appointment saying, “Dr. Kasian brings to the Board a combination of expertise in strategic business leadership and biotech investment, giving him a deep understanding on key value drivers for companies in generating shareholder value, and we are extremely pleased to welcome him as a Director”.

FOR INFORMATION REGARDING THIS ANNOUNCEMENT PLEASE CONTACT

Thomas G. Howitt Company Secretary

Genetic Technologies Limited (ABN 17 009 212 328) Phone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Genetic Technologies Limited
A.B.N.	17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Alexander Kasian
Date of appointment	12 December 2013

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

None

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

	Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest. Yongala Investments Pty. Ltd. ATF Kasian Superannuation Fund	Number & class of Securities 256,410 ordinary shares

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Not applicable Nature of interest Name of registered holder (if issued securities) No. and class of securities to which interest relates

Dated: 12 December 2013

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002